Thus, it is plausible to initiate insulin therapy in patients with diabetes of long duration and suboptimal glycemic control, as shown in the current study (mean duration 8.7–12.1 years, mean HbA1C 8.84–9.50%). The gene discussed is INS; the disease is diabetes mellitus.